| P/E (FY) | — | Sales (TTM) | $4.0M |
| Earnings (TTM) | -$224.6M | ROE | −52.09% |
| Net Margin | −3059.99% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Immunome is a biotechnology company engaged in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. Its clinical asset is Varegacestat, a gamma secretase inhibitor in Phase 3 trials for desmoid tumors, and IM-1021, a ROR1 antibody-drug conjugate in Phase 1. The company is also developing preclinical assets including IM-3050, a radioligand therapy, and solid tumor ADC candidates.
| Market Cap | $2.63B | Trading Days | 1359 |
| 52W High | 27.65 |
| 52W Low | 8.66 |
| % Off High | −16.02% |
| YTD | 8.10% | 1Y | 114.21% |
| 3Y | 211.26% | 5Y | 44.40% |
| Since incept. (ann.) | −5.30% |
Single Reportable 100%
| Ann. Volatility (1Y) | 69.96% | Ann. Volatility (3Y) | 73.82% |
| Sharpe (1Y) | 1.46 | Sharpe (3Y) | 0.90 |
| Max Drawdown (1Y) | −33.59% | Max Drawdown (3Y) | −79.66% |
| Beta (3Y, vs SPY) | 1.44 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc. | $2.62B | — |
| ATAI | AtaiBeckley Inc. | $2.64B | — |
| GRTX | Galera Therapeutics, Inc. | $2.61B | 25.4 |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.56B | — |
| NRIX | Nurix Therapeutics, Inc. | $2.51B | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.77B | — |
| PBH | Prestige Consumer Healthcare Inc. | $2.45B | 13.2 |
| IRON | Disc Medicine, Inc. | $2.85B | — |
| MBX | MBX Biosciences, Inc. | $2.86B | — |
| CUE | Cue Biopharma, Inc. | $2.87B | — |
| VERA | Vera Therapeutics, Inc. | $2.39B |
| — |
| NKTR | NEKTAR THERAPEUTICS | $2.39B | — |
